IP Verse

Chemically Modified Single-Stranded Rna-Editing Oligonucleotides

Patent No. EP3507366 (titled "Chemically Modified Single-Stranded Rna-Editing Oligonucleotides") was filed by Proqr Therapeutics II on Aug 31, 2017. The application was issued on Oct 7, 2020.

Patent Summary

Patent Family

Patent Family

Patent Oppositions

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentative
MARGARET DIXONJun 25, 2021MAIWALD

Dossier Documents

The dossier documents provide a comprehensive record of the patent's prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent's legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents

EP3507366

PROQR THERAPEUTICS II
Application Number
EP17771348A
Filing Date
Aug 31, 2017
Status
Granted And Under Opposition
Sep 4, 2020
Publication Date
Oct 7, 2020
External Links
Slate, Register , Google Patents